Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine.
about
Rhamnose glycoconjugates for the recruitment of endogenous anti-carbohydrate antibodies to tumor cells.Sequence analysis of 96 genomic regions identifies distinct evolutionary lineages within CC156, the largest Streptococcus pneumoniae clonal complex in the MLST database.Structural correlates of carrier protein recognition in tetanus toxoid-conjugated bacterial polysaccharide vaccines.Immunogenicity and protective efficacy of rotavirus VP8* fused to cholera toxin B subunit in a mouse model.Is it worth investigating splenic function in patients with celiac disease?Streptococcus pneumoniae serotype 19A: Worldwide epidemiology.Recent advances in the molecular design of synthetic vaccines.Injection Site Lichenoid Dermatitis Following Pneumococcal Vaccination: Report and Review of Cutaneous Conditions Occurring at Vaccination Sites.The effect of preexisting anti-carrier immunity on subsequent responses to CRM197 or Qb-VLP conjugate vaccines.Myeloid glycosylation defects lead to a spontaneous common variable immunodeficiency-like condition with associated hemolytic anemia and antilymphocyte autoimmunity.A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection.Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae.T Cell-Mediated Humoral Immune Responses to Type 3 Capsular Polysaccharide of Streptococcus pneumoniae.Pneumonia in children: more shadows than lights.
P2860
Q34380952-50B3BB5B-36B1-43AF-8D99-A0D100DFE6D7Q34674449-BE7FCF51-ECF9-4F32-B6F5-F98B04F6B9DAQ35126742-9ECC6F75-4C5E-428F-B05F-F73DB4053924Q37473348-A54F16F7-04B0-4F48-8E24-F116DEB7A04DQ38101325-CE8BD96E-8964-4A81-9504-FE12C1469AFDQ38637072-3DB02F93-9F02-4733-B97F-3FC714B90D95Q38639938-F5996DE3-6AC8-4999-BD4C-CB8855A3BEE8Q38779212-A8D30B4D-5D3B-4A96-87C6-6172F4E84480Q39816694-C748CC05-9C12-4BA7-8D3F-BB3F366F8E39Q40416745-287A5D41-96A6-474A-BA1B-7A2400C9662AQ40462015-6467C711-DC0A-407B-BBEC-3B14C46A517CQ41662682-8870EDEB-0C0C-4E4B-AE5B-2FD12A5A689BQ47134798-74E9C40D-ED16-4363-99E4-9218E84E26E9Q48348733-DD9EE942-89BA-4EAC-888B-D245D75FE942Q50800583-5E4A520B-B4CF-4CCF-9846-9C86FFB85117
P2860
Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Development and clinical evalu ...... ccal CRM197 conjugate vaccine.
@en
type
label
Development and clinical evalu ...... ccal CRM197 conjugate vaccine.
@en
prefLabel
Development and clinical evalu ...... ccal CRM197 conjugate vaccine.
@en
P2093
P2860
P1476
Development and clinical evalu ...... ccal CRM197 conjugate vaccine.
@en
P2093
Daniel A Scott
Emilio A Emini
William C Gruber
P2860
P356
10.1111/J.1749-6632.2012.06673.X
P407
P577
2012-07-25T00:00:00Z